[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-349506-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-349506-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","exploration-of-body-mass-index-and-circulating-metabolic-factors-as-predictors-of-metformin-benefit-in-the-canadian-cancer-trials-group-ma32","Exploration of body mass index and circulating metabolic factors as predictors of metformin benefit in the Canadian Cancer Trials Group MA.32","","Body mass index (BMI) and obesity-associated blood biomarkers were evaluated as predictors of metformin benefit across immunohistochemically defined breast cancer subtypes in the MA.32 randomized adjuvant trial. Among 3649 nondiabetic high-risk early-stage patients, baseline fasting insulin, glucose, leptin, and C-reactive protein were measured, with Homeostasis Model Assessment derived. Cox models tested interactions between BMI or biomarkers and metformin versus placebo for distant recurrence-free survival, overall survival, and invasive disease-free survival.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/exploration-of-body-mass-index-and-circulating-metabolic-factors-as-predictors-of-metformin-benefit-in-the-canadian-cancer-trials-group-ma32/349506/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/exploration-of-body-mass-index-and-circulating-metabolic-factors-as-predictors-of-metformin-benefit-in-the-canadian-cancer-trials-group-ma32/349506.png","ImageObject",300,407,{"name":42,"@type":43},"kopisore","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-05","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the main question of the study in MA.32?","Question",{"text":63,"@type":64},"The study tested whether BMI and obesity-associated blood variables predict metformin benefit across defined breast cancer subtypes in MA.32.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which biomarkers and measures were analyzed at baseline?",{"text":68,"@type":64},"Baseline fasting insulin, glucose, leptin, and C-reactive protein were assayed, and Homeostasis Model Assessment was calculated.",{"name":70,"@type":61,"acceptedAnswer":71},"Did BMI or biomarkers identify groups that benefited from metformin?",{"text":72,"@type":64},"No. BMI and blood variables did not identify subgroups with clear metformin benefit in luminal or triple-negative cancers, and no variable predicted benefit in HER2-positive cancers.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},349506,1790193746,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962090880963,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","JNCI Cancer Spectrum, 2026, 10(4), pkag045  \n[https://doi.org/10.1093/jncics/pkag045](https://doi.org/10.1093/jncics/pkag045)  \nAdvance Access Publication Date: April 30, 2026  \nArticle  \nExploration of body mass index and circulating metabolic factors as predictors of metformin benefit in the Canadian Cancer Trials Group MA.32  \nPamela J. Goodwin , MD􀀃 ,1, Marguerite Ennis , PhD2, Bingshu E. Chen, PhD3, Karen A. Gelmon, MD4, Timothy J. Whelan, MD5, Jennifer A. Ligibel, MD6, Alastair M. Thompson, MBChB, MD7, Lois E. Shepherd, MD8, Wendy R. Parulekar, MD9, Ryan Dowling, PhD10, Vuk Stambolic, PhD11  \n1Department of Medicine and Lunenfeld-Tanenbaum Research Institute, Sinai Health System, University of Toronto, Toronto, ON, Canada 2Applied Statistician, Markham, ON, Canada  \n3Canadian Cancer Trials Group, Department of Public Health Sciences, Queen’s University, Kingston, ON, Canada  \n4Department of Medical Oncology, BC Cancer Agency and Department of Medicine, University of British Columbia, Vancouver, BC, Canada 5Department of Oncology, McMaster University, Hamilton, ON, Canada  \n6Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard University, Boston, MA, United States 7Department of Surgery, Baylor College of Medicine, Houston, TX, United States  \n8Canadian Cancer Trials Group, Department of Pathology and Molecular Medicine, Queens University, Kingston, ON, Canada 9Canadian Cancer Trials Group, Departments of Oncology and Medicine, Queens University, Kingston, ON, Canada 10Roche Canada, Toronto, ON, Canada  \n11Princess Margaret Cancer Centre, University Health Network and Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada  \n􀀃 Corresponding author: Pamela J. Goodwin, MD, Department of Medicine, Mount Sinai Hospital, 1085-600 University Ave, Toronto M5G 1X5, Canada ([pgoodwin@lunenfeld.ca](pgoodwin@lunenfeld.ca)) .  \nAbstract  \nBackground: In the MA.32 randomized adjuvant breast cancer trial, metformin (vs placebo) did not impact invasive disease-free survival or overall survival in estrogen and/or progesterone receptor–positive or –negative breast cancer; exploratory analyses suggested a benefit in HER2-positive breast cancer. We investigated whether body mass index (BMI) and obesity-associated blood variables predicted metformin benefit in immunohistochemically defined breast cancer subtypes (luminal [estrogen/progesterone receptor positive, HER2 negative], triple-negative breast cancer [estrogen receptor, progesterone receptor, HER2 negative], HER2 positive).  \nMethods: A total of 3649 nondiabetic patients with high risk T1-3, N0-3, M0 breast cancer were randomly assigned. Baseline fasting plasma was assayed for insulin, glucose, leptin, and C-reactive protein; Homeostasis Model Assessment was calculated. For each breast cancer subtype and each outcome (distant recurrence free survival, overall survival, invasive disease-free survival), Cox models examined interactions of BMI and blood variables with metformin vs placebo outcomes.  \nResults: Mean age was 51.1-53.0 years; mean BMI was 27.3-27. 5 kg/m2. Most cancers were T2, N0, or N1 and grade 2-3; 2104 (57 .7%) were luminal, 925 (25.3%) TN, and 620 (17.0%) HER2 positive. Median follow-up was 95.9 months. In luminal breast cancer, statistically significant interactions were identified for leptin, insulin, and Homeostasis Model Assessment on distant recurrence–free survival, and in triple-negative breast cancer, a statistically significant interaction was identified for glucose on distant recurrence–free survival, with potential adverse effects of metformin at lower levels of each variable. In those with HER2-positive breast cancer, there was no variable that predicted metformin benefit.  \nConclusions: Body mass index and blood variables did not identify subgroups with luminal or triple-negative breast cancer who benefited from metformin or those with HER2-positive breast cancer who did not benefit.  \nClinical trial registration nu","cbCaimflpfWJozkC","https://ap.wps.com/l/cbCaimflpfWJozkC","pdf",1813233,11,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction\n# Clinical trial registration","[{\"question\":\"What was the main question of the study in MA.32?\",\"answer\":\"The study tested whether BMI and obesity-associated blood variables predict metformin benefit across defined breast cancer subtypes in MA.32.\"},{\"question\":\"Which biomarkers and measures were analyzed at baseline?\",\"answer\":\"Baseline fasting insulin, glucose, leptin, and C-reactive protein were assayed, and Homeostasis Model Assessment was calculated.\"},{\"question\":\"Did BMI or biomarkers identify groups that benefited from metformin?\",\"answer\":\"No. BMI and blood variables did not identify subgroups with clear metformin benefit in luminal or triple-negative cancers, and no variable predicted benefit in HER2-positive cancers.\"}]","Exploration of body mass index and circulating metabolic factors as predictors of metformin benefit in the Canadian Cancer Trials Group MA.32 | PDF",1790083995,28,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/be117dddc3e9a75edfb7821645acb851.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6d75e59ac744b1c63dcb623382bc27e0.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b6d5af514232c42f424fcff1bb24bdc2.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/19dd2b965e4ab351a85f863716de3466.webp",980,1287]